Chiesi USA, Inc. is a specialty pharmaceutical company focused on improving the lives of people with acute, rare, and chronic disorders. As an affiliate of the family-owned global R&D-focused pharmaceutical company, Chiesi Farmaceutici S.p.A, we are dedicated to developing and commercializing products for the hospital, rare diseases, and adjacent specialty care settings. With a strong track record of performance and revenues exceeding $478 million in 2022, Chiesi USA has quickly established itself as a top-producing affiliate in the Chiesi Group. We are committed to sustainability, striving to create a lasting positive impact on patients, customers, and the communities.

The Chiesi Group, headquartered in Parma, Italy, is a global research-focused healthcare group with over 85 years of experience in the pharmaceutical industry. The company focuses on innovative drugs in the respiratory field, rare diseases, and specialist care, employing more than 6,500 people in 31 affiliates worldwide. With over 100 countries distributing therapeutic solutions, the Chiesi Group is among the top 50 pharmaceutical companies in the world, with a consolidated turnover of 2 billion and 749 million euros.